A detailed history of Bank Of America Corp transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 30,120 shares of PBYI stock, worth $75,300. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,120
Previous 15,219 97.91%
Holding current value
$75,300
Previous $80,000 22.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.83 $43,510 - $86,872
14,901 Added 97.91%
30,120 $98,000
Q1 2024

May 15, 2024

SELL
$4.29 - $7.4 $483,551 - $834,098
-112,716 Reduced 88.1%
15,219 $80,000
Q4 2023

Feb 14, 2024

BUY
$2.23 - $4.49 $211,919 - $426,689
95,031 Added 288.81%
127,935 $553,000
Q2 2023

Aug 14, 2023

SELL
$2.6 - $3.58 $52,647 - $72,491
-20,249 Reduced 38.1%
32,904 $116,000
Q1 2023

May 12, 2023

BUY
$2.21 - $4.82 $58,911 - $128,486
26,657 Added 100.61%
53,153 $164,000
Q4 2022

Feb 10, 2023

SELL
$2.12 - $5.08 $72,463 - $173,639
-34,181 Reduced 56.33%
26,496 $112,000
Q3 2022

Nov 14, 2022

SELL
$2.27 - $3.84 $20,475 - $34,636
-9,020 Reduced 12.94%
60,677 $143,000
Q2 2022

Aug 12, 2022

BUY
$1.64 - $3.3 $36,670 - $73,788
22,360 Added 47.24%
69,697 $198,000
Q1 2022

May 16, 2022

SELL
$2.13 - $3.24 $12,897 - $19,618
-6,055 Reduced 11.34%
47,337 $137,000
Q4 2021

Feb 08, 2022

SELL
$2.85 - $6.58 $685,382 - $1.58 Million
-240,485 Reduced 81.83%
53,392 $162,000
Q3 2021

Nov 15, 2021

BUY
$6.63 - $9.39 $111,655 - $158,136
16,841 Added 6.08%
293,877 $2.06 Million
Q2 2021

Sep 13, 2021

BUY
$8.98 - $11.6 $2.49 Million - $3.21 Million
277,036 New
277,036 $2.54 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $114M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.